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Abstract
Background: The tumor cell lysate-pulsed, dendritic cell (DC)-based cancer vaccine approaches are being actively
evaluated for application to cancer immunotherapy, hopefully at a personalized medicine base. There is apparently an
emerging technical problem however, the lack of highly efficacious potency in activation of patient’s DCs for T-cell
priming and the associated process for presenting tumor immunogenicity.
Methods: One strategy to address this is to consider the manipulation of the tumor immunogenic cells death (ICD)
complex ex-vivo for maximal activation of DC efficacy. In our previous study we showed that phytochemical shikonin
(SK) can drastically enhance ICD activity in mouse tumor cells treated ex-vivo, and the resultant tumor cell lysate (TCL)
can effectively augment such SK-TCL pulsed DC vaccine activity in vivo in anti-tumor activities. In this study, we
investigated the specifics and the multi-functional effects of various damaged associated molecular pattern (DAMP)
components of the ICD complex for their participation, roles and potential cross talks in activating DCs, as measured by
five different functional assays.
Results: Among three DAMPs tested, HSP70 and CRT mediate a key role in SK-TCL-induced DC immunity for both CD4
+ and CD8+ T cell proliferations in vitro. HSP70 is the most important component, followed by CRT, then HMGB1 in
facilitating DC immunity on suppressing metastasis of mouse 4 T1 mammary tumors and prolonging survival in test
mice. Only HSP70, but not CRT or HMGB1, is effective for the suppression of both granulocytic and monocytic MDSC
populations in vivo. Both HSP70 and HMGB1, but not CRT, are essential in activating the expression of three key ICD
molecules-associated receptors on test DCs. Each of the three test ICD proteins can exhibit a distinguishable
pattern in stimulating the expression of four key chemokines in test DCs.
Conclusion: Our findings on the differential roles or effect of various ICD components in activating vaccinated DCs may
help formulate new strategies for future cancer vaccine designs.
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Introduction
Simultaneous changes of damage-associated molecular
patterns (DAMPs) associated with immunogenicity, in-
cluding glucose-related protein (GRP), heat shock proteins
(HSP), calreticulin (CRT), high mobility group box 1
(HMGB1) and others are well characterized in mecha-
nisms for immunogenic cell death (ICD) [1]. DAMPs are
found within living cells as a group of natural endogenous
adjuvants, and in response to danger signals, they become
stimulatory to the adaptive immune system [2, 3]. Priming
of an antigen-specific effector T cell response and a strong
T cell immunity can come after the activation of a series
of receptors expressed by dendritic cells (DCs). This same
process also can enable the progression of antigen uptake
and generate an array of molecular activities associated
with the activation of DCs.
Toll-like receptor 4 (TLR4) is essential for sensing
DAMPs, as well as the resultant activation of DCs and the
induction of Th1 response [4, 5]. DAMPs that serve as
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agonists of TLR4 include heat shock proteins (e.g., HSP60,
HSP70, HSP90, HSPB8, and endoplasmin), HMGB1 and
uric acid crystals [4, 5]. Heat shock proteins have attracted
increasing attention due to their ability to chaperone a
wide array of peptides generated in dying cells [6, 7]. In
addition, treatment with chemotherapeutic agents such as
anthracyclines and bortezomib is known to induce a pre-
mortem stress response that exerts immunostimulatory
effects after the exposure of heat shock proteins such as
HSP70 and HSP90 on the surface of dying cancer cells [5].
Some conventional chemotherapeutics (e.g., the nucleo-
side analog gemcitabine) as well as targeted agents [e.g.,
the epidermal growth factor receptor (EGFR) inhibitor, er-
lotinib] result in increased levels of class I or class II MHC
molecules on the tumor cell surface, effectively facilitating
their recognition by the immune system [6, 7]. Chemo-
therapy may thus stimulate the immunogenicity of cancer
cells at multiple levels, and contribute to the induction of
efficient anticancer immune responses [6, 7]. In particular,
HSP-peptide complexes isolated from tumor cells, or
reconstituted by covalent cross-link or fusion-protein
strategies are critical for the loading of MHC-I with epi-
topes, triggering effective tumor-specific T-cell responses
and antitumor effects via cross-presentation by DCs [6, 7].
Shikonin (SK) and its derivatives are the primary active
components isolated from the root tissues of a trad-
itional Chinese medicinal herb, Lithospermum erythror-
hizon and are well-studied bioactive phytochemicals [8].
We previously found that shikonin can effectively induce
the expression of specific DAMPs, which in turn acti-
vated a caspase cascade in treated tumor cells [8]. We
further showed that in combination with pathogen-
associated molecular patterns (PAMPs), such as toll-like
receptors, shikonin-induced tumor cells lysate (SK-TCL)
can activate DCs to phenotypic and functional matur-
ation, which in turn increased the cytotoxic T lympho-
cyte activity contributing to efficacious retardation of
tumor growth and prolonged the survival of test mice
[8]. Our findings suggest that shikonin may serve as an
adjuvant for use in TCL-loaded DC vaccines against can-
cer or other immunotherapeutic applications. However,
the exact mechanisms, signaling pathways and regula-
tory apoptotic molecules that are involved in the process
of immunogenic cell death induced by shikonin are still
unknown.
In this study, we evaluated the role of the key compo-
nents of DAMPs in mediating the interaction between
tumor lysate and treated DCs, and the mechanism by
which anti-tumor immunity is induced by DCs pulsed
with shikonin-treated TCLs. We further analyzed the indi-
vidual involvement of mammary tumor cell-derived ICD
constituents (i.e., HSP70, CRT and HMGB1) in the pro-
motion of the anti-metastatic activity of SK-TCL pulsed
DCs. Within the same context, because doxorubicin
(Dox) has been shown to act as a highly effective immuno-
genic cell death inducer [8], both Dox- and SK-treated
TCLs were analyzed to evaluate the key molecular signals,
which may involve a series of receptors expressed by DCs
for stimulating the presentation of tumor antigens to T
cells. We believe these findings provide important and
specific evidence for use of shikonin in cancer immuno-
therapy, and in the future they may be useful to aid the




Shikonin (SK) was purchased from Tokyo Chemical
Industry (Tokyo, Japan), and doxorubicin (Dox) was from
Sigma (St. Louis, MO, USA). The three antibodies used
for depletion of specific DAMP proteins in tumor cell lys-
ate (TCL) were anti-HSP70 (rabbit plyoclonal; GeneTex),
anti-CRT (rabbit polyclonal; Abcam) and anti-HMGB1
(rabbit plyoclonal; GeneTex). The same antibodies and
anti-β-actin antibody (rabbit polyclonal; Abcam) were also
used as primary antibodies for western blot analyses.
HRP-conjugated secondary antibody (goat polyclonal;
Abcam) was used as a secondary antibody.
Cell lines
Mouse mammary carcinoma cell lines 4 T1 and 4 T1-luc2
(i.e., 4 T1 cells transfected by a firefly luciferase cDNA ex-
pression vector [9] were kindly provided as a gift by Dr.
Hsiao (ABRC, Academia Sinica, Taipei). Transgenic 4 T1-
luc2 cells were employed in the spontaneous metastasis
experimental model after surgical resection of the primary
tumor. The evaluation of bioluminescence signals from
implanted 4 T1-luc2 tumor cells in test mice was per-
formed by using a non-invasive in vivo imaging system
(IVIS) (Calipers, Hopkinton, MA). Both 4 T1 and 4 T1-
luc2 cells were maintained in RPMI-1640 complete
medium (i.e., RPMI-1640 supplemented with 10 % FBS,
100 μM non-essential amino acids, 100 μM sodium
pyruvate, 100 μg/ml streptomycin and 100 unit/ml
penicillin) and grown in a 5 % CO2 incubator at 37 °C.
Preparation of tumor cell lysates
The 4 T1 tumor cell lysate (TCL) samples were prepared
as described previously [9]. Briefly, at 50 % confluence,
4 T1 cells were treated with shikonin (SK) or doxorubi-
cin (Dox) at 5 μM for 24 h for induction of immuno-
genic cell death (ICD). SK- or Dox-treated 4 T1 cells
were then collected and resuspended in PBS, frozen in
liquid nitrogen for 1.5 min and thawed for another
4 min at 4 °C by sonication. The freeze–thaw cycles
were repeated four times. After the final thaw, TCL sus-
pensions were centrifuged at 12,000 rpm for 30 min, and
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the supernatant was used as the source of tumor anti-
gens. Tumor cell lysates were frozen at −80 °C until use.
Antibody-mediated protein depletion for SK-TCLs
The Dynabeads Antibody Coupling Kit (Life Technologies;
14311D) was used to pull down individual intracellular
ICD-related protein molecules in 4 T1 cells according to
the manufacturer’s recommendations, yielding 10 mg
antibody-coupled beads. After the antibody coupling reac-
tion, aliquots of 500 μg SK-TCL were reacted with 2 mg
antibody-coupled beads on a roller shaker at room
temperature for 1 hour. The SK-TCL samples were then
placed on a magnet for 1 min and the beads were
collected along the tube wall. Different preparations of
SK-TCL supernatants, namely [SK-TCL(−HSP70), SK-
TCL(−CRT) and SK-TCL(−HMGB1)] were collected and
used for DC activation experiments.
Mice
Groups of female BALB/c mice aged 6–8 weeks were
purchased from the National Laboratory Animal Breed-
ing and Research Center, Taipei, Taiwan. Experimental
mice were maintained in a standardized laminar airflow
cabinet under specific pathogen-free conditions, and all
manipulation and experimental protocols involving ani-
mals were approved by the IACUC office of Academia
Sinica, Taipei.
Mouse bone marrow-derived dendritic cells
Mouse bone marrow-derived dendritic cells (BMDCs)
were generated and modified as previously described
[10]. Briefly, mouse bone marrow tissues were collected
from BALB/c mice, and erythrocytes were removed. The
derived bone marrow cells were cultured in 30 ml
complete RPMI 1640 medium (see above) supplemented
with 20 ng/mL GM-CSF and 50 μM 2-mercaptoethanol.
Two days later, two-thirds of the original medium was
replaced by 30 mL fresh medium. On day 5, the floating
cells were gently removed and the culture replenished
with fresh medium containing 20 ng/mL GM-CSF and
20 ng/mL IL-4. On day 7, the non-adherent and loosely
adherent DCs in culture were harvested and used as the
source of dendritic cells for various vaccines. DCs were
routinely generated in this manner, and found to be
mainly immature DCs with 85 % of cells expressing
CD11c+, and displaying the typical morphological fea-
tures of DCs.
Dendritic cell activation
The procedure for performing TCL-mediated activation of
BMDCs was performed as previously described [10].
Briefly, BMDCs were incubated for 2 h with various TCL
samples containing 200 μg protein/ml. LPS at 1 μg/ml
was added to the medium for co-cultivation with TCL-
loaded DCs for another 22 h. DC samples treated with
1 μg/ml LPS only for 24 h (mDCs) were used as the ve-
hicle control for TCL stimulation. DC samples reacted
with naive-TCLs (i.e., cell lysates collected from 4 T1
tumor cells that were treated without shikonin or doxo-
rubicin stimulation) were designated as mDCs +Naive-
TCL. DC samples treated with TCLs obtained from 4 T1
cells treated for 24 h with shikonin or doxorubicin stimu-
lation were designated as mDCs + SK-TCL and mDCs +
Dox-TCL, respectively. Similarly, DCs reacted with SK-
TCL samples with which the specific ICD proteins were
depleted with antibodies against HSP70, CRT or HMGB1
were designated as mDCs + SK-TCL(−HSP70), mDCs +
SK-TCL(−CRT) and mDCs + SK-TCL(−HMGB1), respect-
ively. These test DCs were then compared for their activity
in stimulating T-cell proliferation by mixed lymphocyte
reaction (MLR) assay, and for their anti-metastatic effect
on 4 T1 tumors in vivo. The conditional culture media of
test DCs were also collected for cytokine array analysis.
Mixed lymphocyte reaction assay
Mouse CD4+ and CD8+ T cells were isolated by
magnetic activated cell sorting (MACS) selection of
splenocytes with anti-CD4 or anti-CD8 antibody-coated
microbeads (Miltenyi Biotech, Bergisch Gladbach,
NRW), resulting in >98 % purity and >98 % viability in
general. Co-cultivation of the DC-T cell system was
performed as previously described [10, 8]. Briefly, ali-
quots of 1 × 105 CD4+ or CD8+ T cells were co-cultured
with BMDCs (at a DC/T ratio of 1:10) for 4 days in a
final volume of 200 μl medium, and the BMDC-
induced T-cell proliferation activity was determined by
Cell Proliferation ELISA (Roche Applied Science,
Indianapolis, IN).
4 T1 mammary carcinoma-tumor resection model
Mice were injected subcutaneously with 4 T1-Luc2
cells (5 × 105/50 μl PBS/mouse) into the fourth mam-
mary fat pad under isoflurane anesthesia. Tumor
growth was monitored by measuring the tumor volume,
as length × (width)2/2. After tumors were established
(180–200 mm3) on day 15, test mice were divided into
different groups (8 mice/group) and the primary
tumors were surgically resected. For immunization with
DC vaccines, mice were subjected to control treatment
(PBS) or with specific DC vaccines (1 × 106/200 μl PBS/
mouse) via intravenous injection at 0, 7 and 14 days
post tumor resection. To monitor the progression of
metastatic tumors, bioluminescence signals from the
4 T1-luc2 tumor cells in test mice were analyzed using
a non-invasive IVIS imaging system (Calipers, Hopkin-
ton, MA) after intraperitoneal injection of 150 mg/kg
D-luciferin (NanoLight Technology, Pinetop, AZ). For
detection of myeloid-derived suppressor cells (MDSCs),
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peripheral blood cells from test mice were collected at
10 days post the secondary boosting of DC vaccine or
PBS (control). The criteria used to determine humane
endpoint was strictly based on the Guidelines for
Determining Endpoints and Humane Termination of
Animals provided by the Institutional Animal Care and
Use Committee (IACUC) of Academia Sinica, Taiwan.
All test mice were euthanatized by CO2 inhalation at
the end of experiments.
Flow cytometry analysis of surface and intracellular markers
of regulatory T cells and myeloid-derived suppressor cells
For detection of myeloid-derived suppressor cells
(MDSCs), peripheral blood cells from DC vaccine-
immunized and control mice were collected, and leuko-
cytes were stained for 30 min at 4 °C with antibodies
against specific cell markers, including FITC-conjugated
anti-mouse CD11b (for cell surface), APC-Cy7-conjugated
anti-mouse Ly6C and PE-conjugated anti-mouse Ly6G,
(both for intracellular staining). All three antibodies were
obtained from Biolegend, (San Diego, CA). The percent-
ages of monocytic and granulocytic MDSCs were gated on
CD11b+Ly-6C+ cells and CD11b+Ly-6G+ cells, respect-
ively [11], followed by cell permeabilization with the
Cytofix/Cytoperm Plus kit according to the manufac-
turer’s protocol for test antibodies and the reagent kit
from BD Pharmingen (San Diego, CA). Fluorescence sig-
nals were detected by flow cytometry.
Cytokine array analysis
BMDCs (5 × 106/6 ml) were individually incubated with
different TCL samples at 200 μg protein/ml for 2 h and
then treated with LPS (1 μg/ml) for another 22 h. Condi-
tioned culture media of test DCs were collected and ana-
lyzed by Mouse Cytokine Array Panel A (R&D Systems,
Minneapolis, MN). A total of 40 cytokines/chemokines
were analyzed in this assay, which was performed accord-
ing to the manufacturer’s protocol. Briefly, aliquots of 15 μl
cytokine array detection antibody cocktail were added to
each test sample and incubated at room temperature for
one hour. Cytokine array membranes were then incubated
with sample/antibody mixtures overnight at 4 °C on a
shaker. Test samples on membranes were washed 3 times
with 1× wash buffer, each for 10 min. Membranes were
then incubated with Streptavidin-HRP solution for 30 min
at room temperature on a shaker. Membranes were
washed 3 times again as before. Aliquot of 1 ml Chemi
Reagent Mix was added onto each membrane and incu-
bated for 1 min. The membrane was drained and exposed
to X-ray film for 1–20 min. Data were analyzed using
Alpha View SA 3.4 software. Mean values of spotted dupli-
cates were calculated and normalized with the mean values
of reference spots (i.e., internal positive controls). Cyto-
kines/chemokine expression levels were indicated as fold-
change when compared to those of the control group
(mDCs +Naive-TCL).
Western blot assay
Western blot procedures were performed as previously
reported [8]. Tumor cell lysate samples were prepared as
previously described [8, 10]. The 4 T1 TCL protein sam-
ples were resolved by SDS-PAGE using 8, 10 or 15 %
stepwise gels. The resolved proteins were transferred to
a PVDF membrane (Novex, San Diego, CA, USA), and
the membrane was blocked with 5 % non-fat dry milk in
PBST buffer [phosphate-buffered saline (PBS) containing
0.1 % Tween 20] for 60 min at room temperature. The
membranes were incubated with primary antibodies
(1:1000 dilution) overnight at 4 °C, then with HRP-
conjugated secondary antibody (1:100,000 dilution) for
1 h at room temperature, and washed with PBST buffer.
The transferred proteins were visualized with an en-
hanced chemiluminescence (ECL) detection assay kit
(Amersham Pharmacia Biotech, Buckinghamshire, UK).
Quantification of bands was performed using Image J
software.
Statistical analysis
Statistical analysis was performed using an unpaired,
two-tailed Student’s t-test. Statistical analyses were con-
ducted with GraphPad Prism 5.0 (San Diego, CA).
Differences in tumor metastasis mouse survival rate
were determined by a log-rank (Mantel-Cox) test of the
Kaplan-Meier survival curves. All statistical tests were
two-sided. A P-value of less than 0.05 was considered
significant (*, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s, no
significance).
Results
Effect of shikonin-treated 4 T1 tumor cell lysates (SK-TCL)
on DC-activated T-cell proliferation
To evaluate the efficacy of using shikonin-induced
immunogenic cell death (ICD) in tumor cells to enhance
DC-mediated T-cell proliferation activity, test DCs were
stimulated in culture with shikonin-treated 4 T1 tumor cell
lysates (SK-TCL), and the effect of the resultant DCs on T-
cell proliferation was tested by MLR assay. As compared to
treatment with mDCs only, all TCL-treated mDC groups,
including Naive-TCL, SK-TCL and Dox-TCL, were found
to stimulate dose-dependent proliferation of both CD4+
and CD8+ cells (Fig. 1a and 1b, respectively) at a DC/T cell
ratio between 1:1000 and 1:5. At the ratio of 1:5, when
compared to mDC group, the SK-TCL group was found to
significantly induce CD4+ and CD8+ T-cell proliferation up
to 5.27- and 3.53-fold (Fig. 1a and 1b), respectively, as
calculated by the formula [(SK-TCL/iDC)-(mDC/iDC)]/
[(Naive-TCL/iDC)-(mDC/iDC)]. In comparison, Dox-TCL
exhibited only a 3.47- and 2.40-fold change in CD4+ and
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CD8+ T-cell proliferation activities, as shown in Fig. 1a and
1b, respectively. These results suggest that SK-TCL-
activated mDCs can effectively induce the proliferation of
both CD4+ and CD8+ Tcells. These activities were not only
significantly higher than the Naive-TCL group, they were
even moderately higher than those obtained from the Dox-
TCL group.
SK-TCL-activated DCs effectively suppress the metastasis of
4 T1 cells in an orthotopic tumor resection model in vivo
The results outlined above and shown in Fig. 1 suggest
that SK-TCL may possess potential for augmenting T
cell-mediated anti-tumor activity. We therefore next
evaluated the efficacy of use of Naive-TCL, SK-TCL or
Dox-TCL as adjuvants for a DC vaccine formulation
aiming to inhibit tumor metastasis in a mouse 4 T1
mammary tumor-resection model. A bioluminescent,
transgenic luciferase-labeled 4 T1 mouse mammary
carcinoma cell line (a gift provided and developed by
Dr. P.W. Hsiao of Academia Sinica, Taiwan) was used
as a tumor metastasis model in BALB/c mice. At days
0, 7 and 14 post tumor resection, test mice were
injected with different vaccine regimes via tail vein in-
jection. Bioluminescent imaging analysis of mouse tu-
mors was monitored and scored using a non-invasive
in vivo imaging system (IVIS). Among all the test
groups, the SK-TCL vaccine formulation resulted in the
highest and most significant inhibition of tumor metas-
tasis, as seen with the lowest level of luminescent im-
aging of tumor foci (Fig. 2a). When compared with the
mDC (control) group, SK-TCL also showed the stron-
gest anti-tumor metastasis activity, as scored by the
percentage of mice free from metastasis (Fig. 2b). Fig. 2a
and 2b show that more than 50 % of mice in the mDC
group suffered tumor metastasis in the first month after
tumor resection. In contrast, close to 85 % of mice in
Fig. 1 Shikonin-treated 4 T1 tumor cell lysate effectively activates DCs that in turn induce T-cell proliferation in vitro. SK-TCL or Dox-TCL samples were
prepared from transgenic Luc2-labelled 4 T1 cells that were treated with shikinon or doxorubicin at 5 μM for 24 h. Mouse bone marrow-derived DCs
were then treated with Naive-, SK- or Dox-TCL samples and used as stimulator cells. Splenic CD4+ and CD8+ T cells were collected from syngeneic mice
and employed as responder cells. Proliferation activities of a CD4+ and b CD8+ T cells were analyzed by mixed lymphocyte reaction (MLR) assay. Ratios of
stimulator to responder cells were set between 1:1000 and 1:5. T-cell proliferation activity is represented as fold change over the control (T cells only). Data
represent the mean ± SD of three biological replicates, and an independent experiment showed similar results
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the SK-TCL group showed no detectable tumor metas-
tasis. Furthermore, SK-TCL-activated DCs also signifi-
cantly prolonged the survival time of test mice as
compared to the mDC group mice (Fig. 2c). Together,
our findings suggest that the use of SK-TCLs to treat
DCs, as a vaccine formulation strategy, can effectively
Fig. 2 Adjuvant effect of SK-TCL (formulation) used with a DC vaccine, in 4 T1 tumor metastasis in mice. Test mice were injected
subcutaneously with 4 T1-Luc2 cells (5 × 105 cells/100 μl PBS/mouse) into the mammary fat pad under isoflurane anesthesia. At 15 days
post tumor cell implantation, primary tumors were surgically resected. Specifically formulated DC vaccines (1 × 106 DCs/200 μl PBS/mouse) were delivered
via tail vain injection to mice at 0, 7 and 14 days post tumor resection. a Representative in vivo bioluminescent images of test mice (8 mice/group) treated
with PBS, mDCs, mDCs +Naive-TCL, mDCs + SK-TCL and mDCs +Dox-TCL vaccines after resection of the 4 T1 orthotopic primary tumors. The red signals
represent the highest level on the colorimetric scale. b Percentage of whole body (all organs) free from metastasis in mice (8 mice/group). The metastasis
levels of tumors in test mice were scored within the indicated time course as revealed by bioluminescence imaging. c Survival rate of
test mice after resection of 4 T1 tumors and treatment with the indicated DC vaccine regimes. Similar trends of results were obtained
from four independent experiments
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suppress 4 T1 tumor metastasis and prolong the life
span of test mice.
Shikonin effectively increases the expression of HSP70 and
CRT, but not HMGB1, in 4 T1 cells
Certain damage-associated molecular patterns (DAMPs)
are known to play an important role in activating immune
cell-mediated immunogenicity of cancer cells [12, 2, 13].
Furthermore, our results shown in Fig. 2 suggest that shi-
konin (SK) can effectively induce tumor cell ICD, and this
effect constitutes good adjuvant activity for a DC-based
cancer vaccine. To further evaluate the possible specific
roles of the DAMP components in the ICD-associated ac-
tivities of shikonin-treated tumor cells, we next compared
the changes in expression of major ICD components,
HSP70, CRT and HMGB1, in 4 T1 cells in response to SK
treatment. In this experiment, doxorubicin (Dox), which is
known to stimulate ICD [14], was used a positive control.
Treatment with SK at 5 μM for 24 h significantly in-
creased the expression of HSP70 and CRT on mouse 4 T1
mammary tumor cells (Fig. 3), but had little or no effect
on HMGB1 expression (Fig. 3) or other ICD markers
tested (e.g., HSP90) (data not shown). In comparison, Dox
treatment substantially increased the expression of CRT
and HMGB1, but had limited effect on HSP70 expression.
These data suggest that SK and Dox exert a differential ef-
fect on the expression profile of different ICD component
markers, and this difference may contribute to different
mechanisms of ICD and the resultant adjuvant effect on
DC vaccines (see below).
HSP70 and CRT are important DAMP molecules for the
SK-TCL-mediated DC activation of T-cell proliferation
To investigate the possible specific and compartmentalized
effect of different ICD-related protein components (i.e.,
HSP70, CRT and HMGB1) in the SK-TCL complex on the
activity of DC-activated T-cell proliferation, an antibody de-
pletion experiment was performed. Test mDCs were stim-
ulated with SK-TCL or the same complex in which a
single specific ICD component protein (i.e., HSP70, CRT,
or HMGB1) was effectively depleted in vitro by an anti-
body adsorption/pull down procedure. Western blot
analysis (Fig. 4a) showed that the three HSP70-, CRT- and
HMGB1-depleted SK-TCL samples were successfully
obtained, and designated as SK-TCL(−HSP70), SK-
TCL(−CRT) and SK-TCL(−HMGB1), respectively. The
resultant DC-activated T-cell proliferation was then
tested by MLR assay. Test results revealed that the
splenic T-cell proliferative responses were dose depend-
ently increased by co-cultivation of test mDCs, subjected
to treatment with different TCL preparations [i.e., Naive-
TCL, SK-TCL, SK-TCL(−HSP70), SK-TCL(−CRT) and
SK-TCL(−HMGB1)] with test T-cells, at a ratio between
1:100 and 1:5 (DCs:T cells). At the ratio of 1:5, the SK-TCL,
SK-TCL(−HSP70), SK-TCL(−CRT) and SK-TCL(−HMGB1)
test samples showed an approximate 2.9-, 1.3-, 2.2- and
2.3-fold change in CD4+ T-cell proliferation, respectively,
as compared to the control group (Naive-TCL) (Fig. 4b).
In terms of CD8+ T-cell proliferation, activation by DCs
with SK-TCL, SK-TCL(−HSP70), SK-TCL(−CRT) and SK-
TCL(−HMGB1) samples showed an approximate 2.5-, 1.6-,
1.8- and 2.4-fold change in stimulatory activity, respectively,
as compared with the Naive-TCL treated group (Fig. 4c).
Among all tested SK-TCL samples, HSP70-depleted SK-
TCL had the lowest stimulatory effect (i.e., 1.3-fold change)
on CD4+ T-cell proliferation. In comparison, both the
HSP70- and CRT-depleted SK-TCL samples had a similarly
low level of effect (i.e., 1.6- and 1.8-fold change, respect-
ively) on CD8+ T-cell proliferation. Therefore, these results
suggest that HSP70 is the key component of SK-TCL com-
plex that can mediate DC-activated CD4+ and CD8+ T-cell
proliferation; CRT and HMGB-1 proteins seem to play a
“supportive role” in this activity. In comparison, both
HSP70 and CRT appear to play an equally important role
in the proliferation of CD8+ T cells via activation of DCs by
SK-TCL.
HSP70, but not other ICD-related protein components,
plays a key role in the suppression of metastatic 4 T1
malignancies.
As seen in Fig. 4, HSP70 can play a key role in both CD4+
and CD8+ T-cell proliferation in vitro. Therefore, next we
were interested in assessing whether HSP70 also serves as
a major component of the SK-TCL complex that confers
strong adjuvant activity for a DC-based cancer vaccine
Fig. 3 Western blot analyses for expression of HSP70, CRT and HMGB1
in 4 T1 cells. Test 4 T1 cells dispensed in 6-well plates (3 × 105 cells/well)
were incubated with vehicle, SK or Dox at 5 μg/ml for 24 h. Beta-actin
was used as a loading control. Three independent experiments showed
similar patterns as the data shown here
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against metastasis of 4 T1 cells tested in a tumor resection
mouse model. Bioluminescent imaging analysis of mice
treated with control (PBS) and different vaccine adjuvant
formulations [i.e., mDCs +Naive-TCL, mDCs + SK-TCL,
mDCs + SK-TCL(−Hsp70), mDCs + SK-TCL(−CRT) and
mDCs + SK-TCL(−HMGB1)] were scored and analyzed.
As shown in Fig. 5a and 5b, among all the tested groups,
tumor metastasis activity was strongly suppressed in mice
of the mDCs + SK-TCL vaccinated group. However, when
one specific ICD component protein (i.e., HSP70) was de-
pleted, the SK-TCL(−Hsp70) vaccine was found to be
inefficient in promoting the anti-4 T1 metastasis activity
as compared to the mDCs + SK-TCL vaccine (Fig. 5a and
5b). At the third month post tumor resection, half of
the mice of the mDC + SK-TCL vaccine group were free
from tumor metastasis, in contrast, more than 85 %
mice in mDC + SK-TCL(−HSP70) vaccine group suf-
fered tumor metastasis (Fig. 5b). In addition, the sur-
vival time of test mice in the mDCs + SK-TCL(−Hsp70)
group was found to be significantly decreased when
compared to that of the mDC + SK-TCL group
(Fig. 5c).
Fig. 4 HSP70 and CRT may play an important role in shikonin-induced ICD-derived proteins in treated tumor cells, that may differentially activate DCs
and mediate T-cell proliferation. The shikonin-treated 4 T1 cells and the resultant-ICD derived TCLs (i.e., SK-TCL) and the specific protein-deleted SK-TCL
[(i.e., SK-TCL(−HSP70), SK-TCL(−CRT) or SK-TCL(−HMGB1)] were used to stimulate DCs and for subsequent activation of T-cell proliferation. (a) Western
blot analysis of ICD component proteins in SK-TCL(−HSP70), SK-TCL(−CRT) and SK-TCL(−HMGB1) samples, representing specific depletion of HSP70,
CRT or HMGB1 proteins in the correspondent SK-TCL sample preparations, respectively. These DC vaccine samples were then used as stimulator cells
for T-cell proliferation assays. Splenic CD4+ and CD8+ T cells were collected from syngeneic mice as responder cells. Proliferation activities of (b) CD4+
and (c) CD8+ T cells were analyzed by MLR assay. Ratios of stimulator to responder cells were set between at 1:1000 and 1:5. T-cell proliferation activity
is represented as the fold change over the control (T cells only). Data represent the mean ± SD of three replicates. Similar results were obtained from
three independent experiments
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Myeloid-derived suppressor cells (MDSCs) are known
to be an important component for regulation of tumor
growth [15, 16]. The MDSC population consists mainly
of two subsets: cells with granulocytic (gMDSC) pheno-
type expressing Ly6G marker, and cells with monocytic
(mMDSC) phenotype expressing Ly6C marker [17].
Therefore, next we analyzed the possible effect of the
test vaccines on inhibition of both granulocytic and
monocytic MDSCs in immunized animals. The popula-
tions of monocytic and granulocytic MDSCs in periph-
eral blood of test mice were comparatively analyzed at
the third week post tumor resection. As shown in Fig. 5d,
compared with the mDCs + Naive-TCL group, the
CD11b+Ly6C+ and CD11b+Ly6G+ MDSC populations in
mice from the mDCs + SK-TCL group were significantly
decreased, from 30.6 % to 19.6 %, and from 37.6 % to
15.7 %, respectively. When compared to the mDC + SK-
TCL group, mice of the mDCs + SK-TCL(−HSP70)
group exhibited a drastically increased cell population of
CD11b+Ly6C+ and CD11b+Ly6G+ MDSCs, close to
45.5 % and 48.5 %, respectively (Fig. 5d). However, ex-
pansion of the monocytic and granulocytic MDSCs in
mice that were treated with mDCs + SK-TCL(−CRT) or
mDCs + SK-TCL(−HMGB1) exhibited only a 17.0 % and
28.8 % increase (Fig. 5d), respectively. These results sug-
gest that HSP70 plays a highly significant, presumably
Fig. 5 HSP70 may play a key role in the shikonin-induced ICD for enhancing anti-metastasis activity of DC-based cancer vaccines. Specific ICD protein
components (i.e., HSP70, CRT or HMGB1) were depleted from SK-TCL samples before they were used as an adjuvant for preparation of a DC-based cancer
vaccine. Test mice (8 mice/group) were injected with different vaccine formulations [i.e., iDCs, mDCs +Naive-TCL, mDCs + SK-TCL, mDCs + SK-TCL(−HSP70),
mDCs + SK-TCL(−CRT), mDCs + SK-TCL(−HMGB1)] three times (see Materials and Methods), and mice were monitored for metastasis status and survival rate
was scored for three months. a Representative in vivo bioluminescent images of test mice treated with different vaccine regimes after the resection of the
4 T1 orthotopic primary tumors. The red signals represent the highest level on the colorimetric scale. b Percentage of whole body organ free from metastasis
in mice. The metastasis levels of tumors in test mice were scored by bioluminescence imaging within the indicated time period. c Survival rate of test mice
treated with the indicated DC vaccine formulations, after tumor resection. A P value of less than 0.05 was considered significant (*, P< 0.05). d Ten days after
the last vaccination, the percentages of monocytic MDSCs (CD11b+Ly6C+) and granulocytic MDSCs (CD11b+Ly6G+) in the blood of test mice were analyzed
using flow cytometry. Similar trends of results were obtained from three independent experiments shown in (a), (b) and (c), and from two independent
experiments shown in (d)
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major key role in SK-TCL-induced DC immunity, and is
very effective for suppression of both CD11b+Ly6C+
monocytic and CD11b+Ly6G+ granulocytic MDSCs ac-
tivities under in vivo vaccination conditions in mice.
Both HSP70 and HMGB1 in SK-TCL are essential for
activating the secretion of specific chemokines by treated
DCs
Previous studies have shown that specific spectra of cy-
tokines and chemokines are needed to effectively medi-
ate the innate and adoptive immune responses against
tumor growth and metastasis, when mediated through
the recruitment of DCs, monocytes, neutrophils, and T
lymphocytes to the specific tumor sites (Dell'Agnola and
Biragyn, 2007; Dranoff, 2004). Some cytokines and che-
mokines are known to play key roles in recruiting leuko-
cytes or DCs into circulation and enhancing various
cellular immune functions, including T-cell differenti-
ation and polarization (Dranoff, 2004; Griffith et al.,
2014). In order to dissect the functional, and potentially
differential, effect of different ICD-associated molecules
on cytokine/chemokine secretory activity in SK-TCL-
loaded DCs, we analyzed the expression of a series of
immunomodulatory cytokines and chemokines in the
conditioned media of test DCs, using specific cytokine
array analysis. As seen in Fig. 6a and 6b, SK-TCL-loaded
DCs (mDCs + SK-TCL), as compared to Naive-TCL-
loaded DCs (mDCs + Naive-TCL), expressed substan-
tially higher activity in secreting a range of chemotaxis-
related proteins, including SDF-1/CXCL12 (7.86-fold),
Fig. 6 Cytokine profiling array analysis of conditioned culture media
from various 4 T1 TCL-treated DCs. a Cytokine array membranes were
incubated with cultured media from immature DCs or DCs that were
treated with different TCL samples, including Naive-TCL, Dox-TCL, SK-
TCL, SK-TCL(−Hsp70) , SK-TCL(−CRT) and SK-TCL(−HMGB1) for 2 h, and
then stimulated with LPS for another 22 h. Squares mark the chemokines
secreted from DCs that were increased in the SK-TCL-loaded group, as
compared with those from Naive-TCL-loaded groups. Green square: G-
CSF, blue square: SDF-1/CXCL12, red square: MIP-1α/CCL3 and yellow
square: MCP-1/CCL2. b Stimulation (in fold change) of ICD-responsive
chemokines in DCs loaded with Naive-TCL, Dox-TCL, SK-TCL, SK-
TCL(−Hsp70), SK-TCL(−CRT) or SK-TCL(−HMGB1). Secretion level of
each chemokine was normalized by value of Naive-TCL-loaded group
(Fold change = Each TCL-loaded group/Naive-TCL-loaded group). Color
of cone for each chemokine is correspondent to the indication in (a)
Fig. 7 Western blot analyses on expression of CD91, TLR2 and TLR4
proteins on various TCL-activated DCs. Test 4 T1 cells were dispensed in
6-well plates (3 × 105cells/well) and incubated with vehicle, SK or Dox at
5 μg/ml for 24 h. Some sets as replicates collected from SK-TCL samples
were depleted for specific ICD molecules, i.e., HSP70, CRT or HMGB1,
using an antibody-mediated pull-down procedure (see Materials and
Methods). Different ICD molecule-depleted SK-TCL samples were then
compared for their stimulatory activity on expression of CD91, TLR2 and
TLR4 on TCL-pulsed DCs. Beta-actin was used as a loading control. The
results represent the similar trend of data obtained from three
independent experiments
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G-CSF (3.02-fold), MIP-1α/CCL3 (2.57-fold) and MCP-
1/CCL2 (2.41-fold). This result suggests that TCL
collected from metastatic 4 T1 cells exhibiting SK-
induced ICD activity can further enhance the secretory
activity of specific chemokines from treated DCs. To
evaluate the role of individual ICD-related protein compo-
nents in this enhancement activity, an antibody-mediated
protein pull-down experiment was conducted for depletion
of three key ICD component proteins in SK-TCL samples.
In comparison to other test vaccines, SK-TCL(−Hsp70)-
loaded DCs [mDCs + SK-TCL(−Hsp70)] exhibited a signifi-
cantly reduced level of G-CSF (from 3.02- to 0.60-fold),
MIP-1α/CCL3 (from 2.57- to 1.24 fold) and MCP-1/CCL2
(from 2.41- to 1.20-fold), suggesting that HSP-70 has an
important role in activating expression of these chemo-
kines in test DCs. SK-TCL(−HMGB1)-loaded DCs [mDCs
+ SK-TCL(HMGB1)] showed a significantly decreased sec-
retary SDF-1/CXCL12 (from 3.02- to 0.60-fold) and MIP-
1α/CCL3 (from 2.57- to 1.24-fold) activity, suggesting that
HMGB1 can enhance the expression of CXCL12 and
CCL3 in test DCs. The SK-TCL(−CRT)-loaded DCs
[mDCs + SK-TCL(CRT)] resulted only in reduced G-CSF
expression (from 3.02- to 0.79-fold), as compared with SK-
TCL-loaded DCs (Fig. 6a and 6b). Taken together, data
from this cytokine/chemokine profiling experiment further
indicate a distinguishable and differential functional effect
of different ICD-component proteins on TCL-treated DCs,
and these activities in combination may effectively
augment the capacity of DCs to recruit other immune cells
and polarize T cells, resulting in a potent vaccination effect.
HSP70 and HMGB1 in SK-TCL are critical for activation of
the expression of key DAMP-associated receptors on DCs
Previous studies have shown that DAMP molecules, in-
cluding the surface-exposed CRT, secreted ATP, HSP70
and HMGB1, and their interactions with the pattern-
recognition receptors (PRRs), are required for presenting
ICD activity, and this can ultimately lead to the activa-
tion of potent anticancer immunities [13, 18, 19]. In this
study, we were able to detect specific changes in expres-
sion level/pattern of major DAMP-associated receptors
on DCs, including CD91, TLR2 and TLR4, in response
to priming with SK-TCL. In comparison, both Dox-TCL-
and SK-TCL-pulsed DCs expressed much higher levels
of expression of CD91, TLR2 and TLR4 than those de-
tected in immature or Naive-TCL loaded DCs, suggest-
ing specific ICD component proteins from treated
tumor cells can stimulate the expression of these PRRs.
By employing antibody-mediated depletion of specific
ICD components, we further evaluated the role of each
ICD component in stimulating PRR expression on the
vaccinated DCs (Fig. 7). The SK-TCL(−HSP70) and SK-
TCL(−HMGB1) vaccines showed significantly decreased
stimulation of PRR expression on tested DCs. However,
DCs activated by SK-TCL(−CRT) did not show a signifi-
cant change in expression of PRRs (Fig. 7). These results
suggest that both HSP70 and HMGB1 in SK-TCL are
may play a critical role in activating the expression of
key ICD molecules-associated receptors on DCs.
Discussion
Recent studies on immune check point inhibitors, DAMP-
and tumor associated antigen-mediated CTL activities,
anti-MDSC activities, and DC-mediated tumor vaccine
activities against metastatic tumors have generated
renewed clinical interest in evaluating and optimizing can-
cer immunotherapy approaches. It is thus important to
evaluate whether these various immune cell activities may
be mechanistically correlated and clinically coordinated.
The mechanism of export and uptake of DAMPs from im-
munogenic tumor cells to immature DCs remains unclear
and deserves to be extensively explored to improve cancer
vaccine formulation technology. The capacity of specific
and individual DAMP components and their formulation
as a complex in tumor cell lysate-activated DC vaccines to
induce of the proliferation of CD4+ or CD8+ T cells, may
play an important role in future design and development
of anti-cancer vaccines, and hence deserves to be system-
atically studied for potential clinical application. In one of
our previous studies, we demonstrated that shikonin can
effectively induce the expression of specific DAMPs in
treated tumor cells, and these DAMPs can in turn activate
a cascade of caspase activities, which can, in combination,
activate DCs to a full level of maturation and activation,
resulting in potent Th17 and Th1 cell activities that medi-
ate efficacious retardation of tumor growth and prolong
the survival of test mice [8]. In this study, among various
ICD-related protein components, both HSP70 and CRT
were demonstrated to play an essential role in SK-TCL-
induced DC immunity by stimulating both CD4+ and
CD8+ T cell proliferation (Figs. 1 and 4). Our in vivo result
is not in agreement, or perhaps even contradicts, reports
that HMGB1 is the most vital determinant of the im-
munogenicity of ICD to DCs [20, 21]. Moreover, measur-
able differences was also observed in the effects of ICD-
related protein components in tumor vaccine adjuvants
against 4 T1 tumor metastasis and in mouse survival
(Fig. 5a, b, c), i.e., HSP and CRT appear to play a primary
and secondary role in these activities, respectively, and
HMGB1 has limited or low effect.
Myeloid-derived suppressor cells (MDSC) are well
known for their ability to suppress anti-tumor immune
responses [16, 22]. Pre-clinical evidence suggests that
cancer vaccines are more effective in tumor bearing
mice that are depleted of MDSCs [23]. Our results,
shown in Fig. 5d, suggest that HSP70 is a key or perhaps
the only ICD component protein responsible for SK-
TCL-induced alteration of MDSC activities, (including
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both Ly6G+CD11b+ granulocytic MDSCs and CD11b
+Ly6C+ monocytic MDSCs) in test mice. To the best of
our knowledge, the association between HSP70 expres-
sion and MDSC sub-population expansion has not been
previously reported, and our present finding may
warrant a future study on the possible cellular and
molecular link(s) between MDSCs and specific ICD
proteins, or HSP70 in particular, in the tumor tissue
microenvironment, immunity, and the resultant tumor
cell death.
Specific ICD proteins can interact with DAMP-
associated receptors on DCs, such as DC91, TLR2 and
TLR4, and promote the engulfment of dying cells [24].
TLR4 is the major receptor that recognizes the DAMPs
exposed by tumor cells, which can facilitate intracellular
antigen processing and presentation activities. TLR2,
CD40 and CD91 are also known to mediate the binding
and uptake of DAMP’s onto DC’s [25, 26]. Uptake of
necrotic tumor cells can induce maturation of DCs to
prime antigen-specific CD4+ and CD8+ T cells and the
subsequent cellular immune responses [27]. Figure 7
shows that whereas both HSP70 and HMGB1 can play a
key role in activating the expression of CD91, TLR2 and
TLR4 on DCs treated in vitro with shikonin, much less
effect (2–3 fold) was detected for the CRT protein. Cor-
relation between the expression of HSP70 and HMGB1
and the subsequent rise in expressions of DAMP recep-
tors has not been well characterized in previous studies,
and our finding suggests that a positive feedback
mechanism may exist, which can enhance DAMP
receptor-mediated signaling activities in activated DCs.
Currently, the mechanism by which the key DAMPs
direct DC migration and how the signals from these
DAMPs are integrated and processed by the migrating
dendritic cells is poorly understood. Our current study
starts to reveal some of the possible component factors
and their possible role in these highly integrated and
likely programmed cellular and molecular activities. For
instance, both HSP70 and CRT were demonstrated here
to play a more essential role than HMGB1 on induction
of ICD in test tumor cells. For future clinical consider-
ations, we may spike in or supplement, individually or in
combination, relatively high dose of recombinant human
HSP70 or CRT protein preparations into patient’s tumor
cell lysate, creating optimized ICD complex or cell lysate
aggregates for vaccination. In addition, various patient
tumor samples may also be treated ex-vivo in hospital
laboratories with phytochemical shikonin or other simi-
lar adjuvant agents for enhanced expression of ICD pro-
teins, effecting improved stimulation/activation of DC
activities. Furthermore, various cellular and biochemical
assays we used in this study may also be employed as
“pre-vaccination diagnostic assays” for characterizing the
patient’s tumor for modification or/and optimization of
personalized cancer vaccines for specific individual can-
cer patients. With these considerations, we may thus hope
to achieve an improved or enhanced anti-metastatic effect
of future tumor vaccine “formulations”. This could espe-
cially be true if some of such measures could be practiced
in combination with the exciting new immunotherapy
strategy in using anti-PD1, −PDL1, and -CTLA4 anti-
bodies. Taking together, future research is needed to
design and manipulate phytochemicals or other treatment
agents for the ex-vivo induction, engineering or reconsti-
tution of custom made or re-constituted DAMPs that
could be applied as a tailor-made combination or for
specific individual patients, aiming to optimize to the
utmost DC functions for trafficking and priming of T cells
against metastatic tumor cells.
Conclusions
Based on the results of the current study on the specific
and functionally differential roles of three key ICD/
DAMP proteins, mainly including HSP70, CRT and
HMGB1 (Fig. 4, 5 and 6), in SK-induced ICD of tumor
cells, we suggest that a new ex vivo approach may help
rationally design and engineer some of the key compo-
nent DAMPs proteins, in specific molecular ratios
according to specific individual cancer patients’ needs,
to supplement the TCL formulation from cancer
patient’s tumors, i.e., delete, add or reconstitute TCL
components to maximal effect, and thus to employ SK
as an effective adjuvant in development of personalized
dendritic cell-based anticancer vaccines.
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